Monoamine oxidase A

VALUE_ERROR (nil)

Identifiers
Aliases|
External IDs| GeneCards: [1]
Orthologs
Species| Human| Mouse
Entrez| |

n/a

n/a

Ensembl| |

n/a

n/a

UniProt| |

n/a

n/a

RefSeq (mRNA)| |

n/a

n/a

RefSeq (protein)| |

n/a

n/a

Location (UCSC)| n/a| n/a
PubMed search| n/a| n/a
Wikidata
| View/Edit Human|

|

File:MAOA Gene with ChrX Ideogram.svgMAOA gene is located on the short (p) arm of the X chromosome at position 11.3.

Monoamine oxidase A, also known as MAO-A, is an enzyme that in humans is encoded by the MAOA gene.[1][2] This gene is one of two neighboring gene family members that encode mitochondrial enzymes which catalyze the oxidative deamination of amines, such as dopamine, norepinephrine, and serotonin. A mutation of this gene results in Brunner syndrome. This gene has also been associated with a variety of other psychiatric disorders, including antisocial behavior. Alternatively spliced transcript variants encoding multiple isoforms have been observed.[3]

## Contents

* 1 Structure
* 1.1 Gene
* 1.2 Protein
* 2 Function
* 3 Clinical significance
* 3.1 Cancer
* 3.2 Cardiovascular disease
* 3.3 Behavioral and neurological disorders
* 3.3.1 Depression
* 3.3.2 Antisocial behavior
* 3.3.3 Aggression and the "Warrior gene"
* 3.3.4 Legal implications
* 3.3.5 Epigenetics
* 4 Animal studies
* 5 Interactions
* 5.1 Transcription factors
* 5.2 Inducers
* 5.3 Inhibitors
* 6 See also
* 7 References
* 8 Further reading

## Structure

[edit | edit source]

### Gene

[edit | edit source]

Monoamine oxidase A, also known as MAO-A, is an enzyme that in humans is encoded by the MAOA gene.[1][2] The promoter of MAOA contains conserved binding sites for Sp1, GATA2, and TBP.[4] This gene is adjacent to a related gene (MAOB) on the opposite strand of the X chromosome.[citation needed]

In humans, there is a 30-base repeat sequence repeated several different numbers of times in the promoter region of MAO-A. There are 2R (two repeats), 3R, 3.5R, 4R, and 5R variants of the repeat sequence, with the 3R and 4R variants most common in Caucasians. The 3.5R and 4R variants have been found to be more highly active than 3R or 5R, in a study which did not examine the 2R variant.[5]

Studies have found differences in the frequency distribution of variants of the MAOA gene between ethnic groups:[6][7] of the participants, 59% of Black men, 54% of Chinese men, 56% of Maori men, and 34% of Caucasian men carried the 3R allele, while 5.5% of Black men, 0.1% of Caucasian men, and 0.00067% of Asian men carried the 2R allele.[8][6][7][9][10][11][12][13][14][15]

The epigenetic modification of MAOA gene expression through methylation likely plays an important role in women.[16] A study from 2010 found epigenetic methylation of MAOA in men to be very low and with little variability compared to women, while having higher heritability in men than women.[17]

### Protein

[edit | edit source]

The gene encodes a monomeric protein which shares a 70% amino acid sequence identity, as well as conserved chain folds and flavin adenine dinucleotide (FAD)-binding site structures, with MAO-B. However, MAO-A has a monopartite cavity of approximately 550 angstroms, compared to the 290-angstrom bipartite cavity in MAO-B. Nonetheless, both proteins adopt dimeric forms when membrane-bound. The C-terminal domain of MAO-A forms helical tails which are responsible for attaching the protein to the outer mitochondrial membrane (OMM). MAO-A contains loop structures at the entrance of its active site.[18]

## Function

[edit | edit source]

MAO-A is a key regulator for normal brain function. It is a flavoenzyme which degrades amine neurotransmitters, such as dopamine, norepinephrine, and serotonin, via oxidative deamination. It is highly expressed in neural and cardiac cells and localizes to the outer mitochondrial membrane. Its expression is regulated by the transcription factors SP1, GATA2, and TBP via the CAMP pathway in response to stress such as ischemia and inflammation.[4]

## Clinical significance

[edit | edit source]

### Cancer

[edit | edit source]

MAO-A produces an amine oxidase, which is a class of enzyme known to affect carcinogenesis. Clorgyline, an MAO-A enzyme inhibitor, prevents apoptosis in melanoma cells, in vitro.[19] Cholangiocarcinoma suppresses MAO-A expression, and those patients with higher MAO-A expression had less adjacent organ invasion and better prognosis and survival.[20]

### Cardiovascular disease

[edit | edit source]

MAOA activity is linked to apoptosis and cardiac damage during cardiac injury following ischemic-reperfusion.[4]

### Behavioral and neurological disorders

[edit | edit source]

There is a link between low activities forms of the MAOA gene and autism.[21] Mutations in the MAOA gene results in monoamine oxidase deficiency, or Brunner syndrome.[3] Other disorders associated with MAO-A include Alzheimer's disease, aggression, panic disorder, bipolar affective disorder, major depressive disorder, and attention deficit hyperactivity disorder.[4] Effects of parenting on self-regulation in adolescents appear to be moderated by 'plasticity alleles', of which the 2R and 3R alleles of MAOA are two, with "the more plasticity alleles males (but not females) carried, the more and less self-regulation they manifested under, respectively, supportive and unsupportive parenting conditions."[22]

#### Depression

[edit | edit source]

MAO-A levels in the brain as measured using positron emission tomography are elevated by an average of 34% in patients with major depressive disorder.[23] Genetic association studies examining the relationship between high-activity MAOA variants and depression have produced mixed results, with some studies linking the high-activity variants to major depression in females,[24] depressed suicide in males,[25] major depression and sleep disturbance in males[26] and major depressive disorder in both males and females.[27]

Other studies failed to find a significant relationship between high-activity variants of the MAOA gene and major depressive disorder.[28][29] In patients with major depressive disorder, those with MAOA G/T polymorphisms (rs6323) coding for the highest-activity form of the enzyme have a significantly lower magnitude of placebo response than those with other genotypes.[30]

#### Antisocial behavior

[edit | edit source]

In humans, an association between the 2R allele of the VNTR region of the gene and an increase in the likelihood of committing serious crime or violence has been found.[5][31][8]

A connection between the MAO-A gene 3R version and several types of anti-social behaviour has been found: Maltreated children with genes causing high levels of MAO-A were less likely to develop antisocial behavior.[32] Low MAO-A activity alleles which are overwhelmingly the 3R allele in combination with abuse experienced during childhood resulted in an increased risk of aggressive behaviour as an adult,[33] and men with the low activity MAOA allele were more genetically vulnerable even to punitive discipline as a predictor of antisocial behaviour.[34] High testosterone, maternal tobacco smoking during pregnancy, poor material living standards, dropping out of school, and low IQ predicted violent behavior are associated with men with the low-activity alleles.[35][36] The low-activity 3-repeat allele variant of the MAOA gene has also been found to occur frequently in men who join gangs.[37] According to a large meta-analysis in 2014, the 3R allele had a small main effect on aggression and antisocial behavior, even in the absence of other interaction factors.[38]

#### Aggression and the "Warrior gene"

[edit | edit source]

A variant of the monoamine oxidase-A gene has been popularly referred to as the warrior gene.[39] Several different versions of the gene are found in different individuals, although a functional gene is present in most humans (with the exception of a few individuals with Brunner syndrome).[40] In the variant, the allele associated with behavioural traits is shorter (30 bases) and may produce less MAO-A enzyme.[6] This gene variation is in a regulatory promoter region about 1,000 bases from the start of the region that encodes the MAO-A enzyme.

When faced with social exclusion or ostracism, individuals with the low activity MAOA gene showed higher levels of aggression than individuals with the high activity MAOA gene.[41] Low activity MAO-A could significantly predict aggressive behaviour in a high provocation situation, but was less associated with aggression in a low provocation situation. Individuals with the low activity variant of the MAOA gene were just as likely as participants with the high activity variant to retaliate when the loss was small. However, they were more likely to retaliate and with greater force when the loss was large.[42]

"Monoamine oxidases (MAOs) are enzymes that are involved in the breakdown of neurotransmitters such as serotonin and dopamine and are, therefore, capable of influencing feelings, mood, and behaviour of individuals".[43] According to this, if there was a mutation to the gene that is involved in the process of promoting or inhibiting MAO enzymes, it could affect a person's personality or behaviour and could therefore make them more prone to aggression. A deficiency in the MAOA gene has shown higher levels of aggression in males, which could further stimulate more research into this controversial topic. "A deficiency in monoamine oxidase A (MAO-A) has been shown to be associated with aggressive behaviour in men of a Dutch family".[44]

#### Legal implications

[edit | edit source]

In a 2009 criminal trial in the United States, an argument based on a combination of "warrior gene" and history of child abuse was successfully used to avoid a conviction of first-degree murder and the death penalty; however, the convicted murderer was sentenced to 32 years in prison.[45][46] The results showed the effects of the 4-repeat allele of MAOA promoter polymorphism on physical aggressive behavior for women. It seems that there is an interaction between the 3-repeat allele of MAOA promoter polymorphism and emotional abuse experiences on aggressive behavior for women.[45]

#### Epigenetics

[edit | edit source]

Studies have linked methylation of the MAOA gene with nicotine and alcohol dependence in women.[47] A second MAOA VNTR promoter, P2, influences epigenetic methylation and interacts with having experienced child abuse to influence antisocial personality disorder symptoms, only in women.[48]

## Animal studies

[edit | edit source]

A dysfunctional MAOA gene has been correlated with increased aggression levels in mice,[49][50] and has been correlated with heightened levels of aggression in humans.[51] In mice, a dysfunctional MAOA gene is created through insertional mutagenesis (called ‘Tg8’).[49] Tg8 is a transgenic mouse strain that lacks functional MAO-A enzymatic activity. Mice that lacked a functional MAOA gene exhibited increased aggression towards intruder mice.[49][52]

Some types of aggression exhibited by these mice were territorial aggression, predatory aggression, and isolation-induced aggression.[50] The MAO-A deficient mice that exhibited increased isolation-induced aggression reveals that an MAO-A deficiency may also contribute to a disruption in social interactions.[53] There is research in both humans and mice to support that a nonsense point mutation in the eighth exon of the MAOA gene is responsible for impulsive aggressiveness due to a complete MAO-A deficiency.[49][51]

## Interactions

[edit | edit source]

### Transcription factors

[edit | edit source]

A number of transcription factors bind to the promoter region of MAO-A and upregulate its expression. These include:Sp1 transcription factor, GATA2, TBP.[4]

### Inducers

[edit | edit source]

Synthetic compounds that up-regulate the expression of MAO-A include Valproic acid (Depakote)[54]

### Inhibitors

[edit | edit source]

Main articles: Reversible inhibitor of monoamine oxidase A and Monoamine oxidase inhibitor

Substances that inhibit the enzymatic activity of MAO-A include:

* Synthetic compounds
* Befloxatone (MD370503)
* Brofaromine (Consonar)
* Cimoxatone
* Clorgyline (irreversible)
* Methylene Blue
* Minaprine (Cantor)
* Moclobemide (Aurorix, Manerix)
* Phenelzine (Nardil)
* Pirlindole (Pirazidol)
* Toloxatone (Humoryl)
* Tyrima (CX 157)
* Tranylcypromine (nonselective and irreversible)
* Natural products
* Incarviatone A
* Herbal sources
* Curcumin (Turmeric)
* Garlic (Garlic)
* Harmala Alkaloids (Syrian Rue, Passion Flower, Ayahuasca)
* Harmine
* Harmaline

## See also

[edit | edit source]

* Monoamine oxidase B

## References

[edit | edit source]

1. ↑ 1.0 1.1 Hotamisligil GS, Breakefield XO (Aug 1991). "Human monoamine oxidase A gene determines levels of enzyme activity". American Journal of Human Genetics. 49 (2): 383–92. PMC 1683299. PMID 1678250.
2. ↑ 2.0 2.1 Grimsby J, Chen K, Wang LJ, Lan NC, Shih JC (May 1991). "Human monoamine oxidase A and B genes exhibit identical exon-intron organization". Proceedings of the National Academy of Sciences of the United States of America. 88 (9): 3637–41. doi:10.1073/pnas.88.9.3637. PMC 51507. PMID 2023912.
3. ↑ 3.0 3.1 "Entrez Gene: MAOA monoamine oxidase A".
4. ↑ 4.0 4.1 4.2 4.3 4.4 Gupta V, Khan AA, Sasi BK, Mahapatra NR (Jul 2015). "Molecular mechanism of monoamine oxidase A gene regulation under inflammation and ischemia-like conditions: key roles of the transcription factors GATA2, Sp1 and TBP". Journal of Neurochemistry. 134 (1): 21–38. doi:10.1111/jnc.13099. PMID 25810277.
5. ↑ 5.0 5.1 Guo G, Ou XM, Roettger M, Shih JC (May 2008). "The VNTR 2 repeat in MAOA and delinquent behavior in adolescence and young adulthood: associations and MAOA promoter activity". European Journal of Human Genetics. 16 (5): 626–34. doi:10.1038/sj.ejhg.5201999. PMC 2922855. PMID 18212819.
6. ↑ 6.0 6.1 6.2 Sabol SZ, Hu S, Hamer D (Sep 1998). "A functional polymorphism in the monoamine oxidase A gene promoter". Human Genetics. 103 (3): 273–9. doi:10.1007/s004390050816. PMID 9799080.
7. ↑ 7.0 7.1 Lea R, Chambers G (2007). "Monoamine oxidase, addiction, and the "warrior" gene hypothesis". The New Zealand Medical Journal. 120 (1250): U2441. PMID 17339897.
8. ↑ 8.0 8.1 Beaver KM, et al. (2012). "Exploring the association between the 2-repeat allele of the MAOA gene promoter polymorphism and psychopathic personality traits, arrests, incarceration, and lifetime antisocial behavior". Personality and Individual Differences. 54 (2): 164–168. doi:10.1016/j.paid.2012.08.014.
9. ↑ Lu RB, Lin WW, Lee JF, Ko HC, Shih JC (Jun 2003). "Neither antisocial personality disorder nor antisocial alcoholism is associated with the MAO-A gene in Han Chinese males". Alcoholism: Clinical and Experimental Research. 27 (6): 889–93. doi:10.1097/01.ALC.0000071927.64880.0E. PMID 12824808.
10. ↑ Zhang M, Chen X, Way N, Yoshikawa H, Deng H, Ke X, Yu W, Chen P, He C, Chi X, Lu Z (Sep 2011). "The association between infants' self-regulatory behavior and MAOA gene polymorphism". Developmental Science. 14 (5): 1059–65. doi:10.1111/j.1467-7687.2011.01047.x. PMID 21884321.
11. ↑ Zhou Q, Hofer C, Eisenberg N, Reiser M, Spinrad TL, Fabes RA (Mar 2007). "The developmental trajectories of attention focusing, attentional and behavioral persistence, and externalizing problems during school-age years". Developmental Psychology. 43 (2): 369–385. doi:10.1037/0012-1649.43.2.369. PMC 1832154. PMID 17352545.
12. ↑ Chen SY, Wang J, Yu GQ, Liu W, Pearce D (May 1997). "Androgen and glucocorticoid receptor heterodimer formation. A possible mechanism for mutual inhibition of transcriptional activity". The Journal of Biological Chemistry. 272 (22): 14087–92. doi:10.1074/jbc.272.22.14087. PMID 9162033.
13. ↑ Ono H, Shirakawa O, Nishiguchi N, Nishimura A, Nushida H, Ueno Y, Maeda K (Apr 2002). "No evidence of an association between a functional monoamine oxidase a gene polymorphism and completed suicides". American Journal of Medical Genetics. 114 (3): 340–2. doi:10.1002/ajmg.10237. PMID 11920860.
14. ↑ Wang TJ, Huang SY, Lin WW, Lo HY, Wu PL, Wang YS, Wu YS, Ko HC, Shih JC, Lu RB (Jan 2007). "Possible interaction between MAOA and DRD2 genes associated with antisocial alcoholism among Han Chinese men in Taiwan". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 31 (1): 108–114. doi:10.1016/j.pnpbp.2006.08.010. PMID 17007976.
15. ↑ Lee SY, Hahn CY, Lee JF, Huang SY, Chen SL, Kuo PH, Lee IH, Yeh TL, Yang YK, Chen SH, Ko HC, Lu RB (Jul 2010). "MAOA interacts with the ALDH2 gene in anxiety-depression alcohol dependence". Alcoholism: Clinical and Experimental Research. 34 (7): 1212–8. doi:10.1111/j.1530-0277.2010.01198.x. PMID 20477771.
16. ↑ Jiang Y, Langley B, Lubin FD, Renthal W, Wood MA, Yasui DH, Kumar A, Nestler EJ, Akbarian S, Beckel-Mitchener AC (Nov 2008). "Epigenetics in the nervous system". The Journal of Neuroscience. 28 (46): 11753–9. doi:10.1523/JNEUROSCI.3797-08.2008. PMID 19005036.
17. ↑ Wong CC, Caspi A, Williams B, Craig IW, Houts R, Ambler A, Moffitt TE, Mill J (Aug 2010). "A longitudinal study of epigenetic variation in twins". Epigenetics. 5 (6): 516–26. doi:10.4161/epi.5.6.12226. PMC 3322496. PMID 20505345.
18. ↑ Binda C, Mattevi A, Edmondson DE (2011). "Structural properties of human monoamine oxidases a and B". Monoamine Oxidase and their Inhibitors. International Review of Neurobiology. 100. pp. 1–11. doi:10.1016/B978-0-12-386467-3.00001-7. ISBN 9780123864673. PMID 21971000.
19. ↑ Pietrangeli P, Mondovì B (Jan 2004). "Amine oxidases and tumors". Neurotoxicology. 25 (1–2): 317–24. doi:10.1016/S0161-813X(03)00109-8. PMID 14697906.
20. ↑ Huang L, Frampton G, Rao A, Zhang KS, Chen W, Lai JM, Yin XY, Walker K, Culbreath B, Leyva-Illades D, Quinn M, McMillin M, Bradley M, Liang LJ, DeMorrow S (Oct 2012). "Monoamine oxidase A expression is suppressed in human cholangiocarcinoma via coordinated epigenetic and IL-6-driven events". Laboratory Investigation. 92 (10): 1451–60. doi:10.1038/labinvest.2012.110. PMID 22906985.
21. ↑ Cohen IL, Liu X, Lewis ME, Chudley A, Forster-Gibson C, Gonzalez M, Jenkins EC, Brown WT, Holden JJ (Apr 2011). "Autism severity is associated with child and maternal MAOA genotypes". Clinical Genetics. 79 (4): 355–62. doi:10.1111/j.1399-0004.2010.01471.x. PMID 20573161.
22. ↑ Belsky J, Beaver KM (May 2011). "Cumulative-genetic plasticity, parenting and adolescent self-regulation". Journal of Child Psychology and Psychiatry. 52 (5): 619–626. doi:10.1111/j.1469-7610.2010.02327.x. PMC 4357655. PMID 21039487.
23. ↑ Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A, Young T, Praschak-Rieder N, Wilson AA, Houle S (Nov 2006). "Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression". Archives of General Psychiatry. 63 (11): 1209–16. doi:10.1001/archpsyc.63.11.1209. PMID 17088501.
24. ↑ Schulze TG, Müller DJ, Krauss H, Scherk H, Ohlraun S, Syagailo YV, Windemuth C, Neidt H, Grässle M, Papassotiropoulos A, Heun R, Nöthen MM, Maier W, Lesch KP, Rietschel M (Dec 2000). "Association between a functional polymorphism in the monoamine oxidase A gene promoter and major depressive disorder". American Journal of Medical Genetics. 96 (6): 801–3. doi:10.1002/1096-8628(20001204)96:6<801::AID-AJMG21>3.0.CO;2-4. PMID 11121185.
25. ↑ Du L, Faludi G, Palkovits M, Sotonyi P, Bakish D, Hrdina PD (Jul 2002). "High activity-related allele of MAO-A gene associated with depressed suicide in males". NeuroReport. 13 (9): 1195–8. doi:10.1097/00001756-200207020-00025. PMID 12151768.
26. ↑ Du L, Bakish D, Ravindran A, Hrdina PD (Sep 2004). "MAO-A gene polymorphisms are associated with major depression and sleep disturbance in males". NeuroReport. 15 (13): 2097–101. doi:10.1097/00001756-200409150-00020. PMID 15486489.
27. ↑ Yu YW, Tsai SJ, Hong CJ, Chen TJ, Chen MC, Yang CW (Sep 2005). "Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response". Neuropsychopharmacology. 30 (9): 1719–23. doi:10.1038/sj.npp.1300785. PMID 15956990.
28. ↑ Serretti A, Cristina S, Lilli R, Cusin C, Lattuada E, Lorenzi C, Corradi B, Grieco G, Costa A, Santorelli F, Barale F, Nappi G, Smeraldi E (May 2002). "Family-based association study of 5-HTTLPR, TPH, MAO-A, and DRD4 polymorphisms in mood disorders". American Journal of Medical Genetics. 114 (4): 361–9. doi:10.1002/ajmg.10356. PMID 11992558.
29. ↑ Huang SY, Lin MT, Lin WW, Huang CC, Shy MJ, Lu RB (2009). "Association of monoamine oxidase A (MAOA) polymorphisms and clinical subgroups of major depressive disorders in the Han Chinese population". The World Journal of Biological Psychiatry. 10 (4 Pt 2): 544–51. doi:10.1080/15622970701816506. PMID 19224413.
30. ↑ Leuchter AF, McCracken JT, Hunter AM, Cook IA, Alpert JE (Aug 2009). "Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder". Journal of Clinical Psychopharmacology. 29 (4): 372–7. doi:10.1097/JCP.0b013e3181ac4aaf. PMID 19593178.
31. ↑ Guo G, Roettger M, Shih JC (August 2008). "The integration of genetic propensities into social-control models of delinquency and violence among male youths" (PDF). American Sociological Review. 73 (4): 543–568. doi:10.1177/000312240807300402. Archived from the original (PDF) on December 2, 2008. Retrieved 2009-02-16.
32. ↑ Caspi A, McClay J, Moffitt TE, Mill J, Martin J, Craig IW, Taylor A, Poulton R (Aug 2002). "Role of genotype in the cycle of violence in maltreated children". Science. 297 (5582): 851–4. doi:10.1126/science.1072290. PMID 12161658. Lay summary - eurekalert.org (2002-08-01).
33. ↑ Frazzetto G, Di Lorenzo G, Carola V, Proietti L, Sokolowska E, Siracusano A, Gross C, Troisi A (2007). "Early trauma and increased risk for physical aggression during adulthood: the moderating role of MAOA genotype". PLOS ONE. 2 (5): e486. doi:10.1371/journal.pone.0000486. PMC 1872046. PMID 17534436.
34. ↑ Choe DE, Shaw DS, Hyde LW, Forbes EE (September 2014). "Interactions Between Monoamine Oxidase A and Punitive Discipline in African American and Caucasian Men's Antisocial Behavior". Clinical Psychological Science. 2 (5): 591–601. doi:10.1177/2167702613518046.
35. ↑ Fergusson DM, Boden JM, Horwood LJ, Miller A, Kennedy MA (Feb 2012). "Moderating role of the MAOA genotype in antisocial behaviour". The British Journal of Psychiatry. 200 (2): 116–23. doi:10.1192/bjp.bp.111.093328. PMID 22297589.
36. ↑ Sjöberg RL, Ducci F, Barr CS, Newman TK, Dell'osso L, Virkkunen M, Goldman D (Jan 2008). "A non-additive interaction of a functional MAO-A VNTR and testosterone predicts antisocial behavior". Neuropsychopharmacology. 33 (2): 425–30. doi:10.1038/sj.npp.1301417. PMC 2665792. PMID 17429405.
37. ↑ The role of gene-gene interaction in the prediction of criminal behavior.
38. ↑ Ficks CA, Waldman ID (Sep 2014). "Candidate genes for aggression and antisocial behavior: a meta-analysis of association studies of the 5HTTLPR and MAOA-uVNTR". Behavioral Genetics. 44 (5): 427–44. doi:10.1007/s10519-014-9661-y. PMID 24902785.
39. ↑ Hogenboom M (28 October 2014). "Share this pageEmail Print Share this page". BBC News. Retrieved 2014-11-01.
40. ↑ Online Mendelian Inheritance in Man (OMIM) MONOAMINE OXIDASE A; MAOA. -309850
41. ↑ Gallardo-Pujol D, Andrés-Pueyo A, Maydeu-Olivares A (Feb 2013). "MAOA genotype, social exclusion and aggression: an experimental test of a gene-environment interaction". Genes, Brain, and Behavior. 12 (1): 140–145. doi:10.1111/j.1601-183X.2012.00868.x. PMID 23067570.
42. ↑ McDermott R, Tingley D, Cowden J, Frazzetto G, Johnson DD (Feb 2009). "Monoamine oxidase A gene (MAOA) predicts behavioral aggression following provocation". Proceedings of the National Academy of Sciences of the United States of America. 106 (7): 2118–23. doi:10.1073/pnas.0808376106. PMC 2650118. PMID 19168625.
43. ↑ Hook GR (2009). ""Warrior genes" and the disease of being Māori". MAI Review (2): 1–11.
44. ↑ Cases O, Seif I, Grimsby J, Gaspar P, Chen K, Pournin S, Müller U, Aguet M, Babinet C, Shih JC (Jun 1995). "Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA". Science. 268 (5218): 1763–6. doi:10.1126/science.7792602. PMC 2844866. PMID 7792602.
45. ↑ 45.0 45.1 Barber N (2010-07-13). "Pity the poor murderer, his genes made him do it". Psychology Today. Blog: "The Human Beast: Why we do what we do". Retrieved 2010-10-17.
46. ↑ Hagerty BB (2010-07-01). "Can Your Genes Make You Murder?". News > Science > Inside The Criminal Brain. National Public Radio. Retrieved 2010-10-17.
47. ↑ Philibert RA, Gunter TD, Beach SR, Brody GH, Madan A (Jul 2008). "MAOA methylation is associated with nicotine and alcohol dependence in women". American Journal of Medical Genetics Part B. 147B (5): 565–70. doi:10.1002/ajmg.b.30778. PMC 3685146. PMID 18454435.
48. ↑ Philibert RA, Wernett P, Plume J, Packer H, Brody GH, Beach SR (Jul 2011). "Gene environment interactions with a novel variable Monoamine Oxidase A transcriptional enhancer are associated with antisocial personality disorder". Biological Psychology. 87 (3): 366–71. doi:10.1016/j.biopsycho.2011.04.007. PMC 3134149. PMID 21554924.
49. ↑ 49.0 49.1 49.2 49.3 Scott AL, Bortolato M, Chen K, Shih JC (May 2008). "Novel monoamine oxidase A knock out mice with human-like spontaneous mutation". NeuroReport. 19 (7): 739–43. doi:10.1097/WNR.0b013e3282fd6e88. PMC 3435113. PMID 18418249.
50. ↑ 50.0 50.1 Vishnivetskaya GB, Skrinskaya JA, Seif I, Popova NK (2007). "Effect of MAO A deficiency on different kinds of aggression and social investigation in mice". Aggressive Behavior. 33 (1): 1–6. doi:10.1002/ab.20161. PMID 17441000.
51. ↑ 51.0 51.1 Brunner HG, Nelen M, Breakefield XO, Ropers HH, van Oost BA (Oct 1993). "Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A". Science. 262 (5133): 578–80. doi:10.1126/science.8211186. PMID 8211186.
52. ↑ Vishnivetskaya GB, Skrinskaya JA, Seif I, Popova NK (1 January 2007). "Effect of MAO A deficiency on different kinds of aggression and social investigation in mice". Aggressive Behavior. 33 (1): 1–6. doi:10.1002/ab.20161. PMID 17441000.
53. ↑ Hebebrand J, Klug B (Sep 1995). "Specification of the phenotype required for men with monoamine oxidase type A deficiency". Human Genetics. 96 (3): 372–6. doi:10.1007/BF00210430. PMID 7649563.
54. ↑ Wu JB, Shih JC (Oct 2011). "Valproic acid induces monoamine oxidase A via Akt/forkhead box O1 activation". Molecular Pharmacology. 80 (4): 714–723. doi:10.1124/mol.111.072744. PMC 3187529. PMID 21775495.

## Further reading

[edit | edit source]

* Rehan W, Sandnabba NK, Johansson A, Westberg L, Santtila P (October 2015). "Effects of MAOA genotype and childhood experiences of physical and emotional abuse on aggressive behavior in adulthood". Nordic Psychology. 67 (4): 301–12. doi:10.1080/19012276.2015.1026922.
* McDermott R, Tingley D, Cowden J, Frazzetto G, Johnson DD (Feb 2009). "Monoamine oxidase A gene (MAOA) predicts behavioral aggression following provocation". Proceedings of the National Academy of Sciences of the United States of America. 106 (7): 2118–23. doi:10.1073/pnas.0808376106. PMC 2650118. PMID 19168625.
* Edmondson DE, Binda C, Mattevi A (Jan 2004). "The FAD binding sites of human monoamine oxidases A and B". Neurotoxicology. 25 (1–2): 63–72. doi:10.1016/S0161-813X(03)00114-1. PMID 14697881.
* Craig IW (Mar 2007). "The importance of stress and genetic variation in human aggression". BioEssays. 29 (3): 227–36. doi:10.1002/bies.20538. PMID 17295220.

| Wikimedia Commons has media related to Monoamine oxidase A.

|

* v
* t
* e

PDB gallery

* 2bxr: HUMAN MONOAMINE OXIDASE A IN COMPLEX WITH CLORGYLINE, CRYSTAL FORM A

2bxr: HUMAN MONOAMINE OXIDASE A IN COMPLEX WITH CLORGYLINE, CRYSTAL FORM A

* 2bxs: HUMAN MONOAMINE OXIDASE A IN COMPLEX WITH CLORGYLINE, CRYSTAL FORM B

2bxs: HUMAN MONOAMINE OXIDASE A IN COMPLEX WITH CLORGYLINE, CRYSTAL FORM B

* v
* t
* e

Mitochondrial proteins

Outer membrane|

| fatty acid degradation|

* Carnitine palmitoyltransferase I
* Long-chain-fatty-acid—CoA ligase

|

tryptophan metabolism|

* Kynureninase

monoamine neurotransmitter
metabolism|

* Monoamine oxidase

Intermembrane space|

* Adenylate kinase
* Creatine kinase

Inner membrane|

| oxidative phosphorylation|

* Coenzyme Q – cytochrome c reductase
* Cytochrome c
* NADH dehydrogenase
* Succinate dehydrogenase

|

pyrimidine metabolism|

* Dihydroorotate dehydrogenase

mitochondrial shuttle|

* Malate-aspartate shuttle
* Glycerol phosphate shuttle

other|

* Glutamate aspartate transporter
* Glycerol-3-phosphate dehydrogenase
* ATP synthase
* Carnitine palmitoyltransferase II
* Uncoupling protein

Matrix|

| citric acid cycle|

* Citrate synthase
* Aconitase
* Isocitrate dehydrogenase
* Oxoglutarate dehydrogenase complex
* Succinyl coenzyme A synthetase
* Fumarase
* Malate dehydrogenase

|

anaplerotic reactions|

* Aspartate transaminase
* Glutamate dehydrogenase
* Pyruvate dehydrogenase complex

urea cycle|

* Carbamoyl phosphate synthetase I
* Ornithine transcarbamylase
* N-Acetylglutamate synthase

alcohol metabolism|

* ALDH2

* PMPCB

Other/to be sorted|

| steroidogenesis|

* Cholesterol side-chain cleavage enzyme
* Steroid 11-beta-hydroxylase
* Aldosterone synthase
* Frataxin

|

* Mitochondrial membrane transport protein
* Mitochondrial permeability transition pore
* Mitochondrial carrier

Mitochondrial DNA|

| Complex I|

* MT-ND1
* MT-ND2
* MT-ND3
* MT-ND4
* MT-ND4L
* MT-ND5
* MT-ND6

|

Complex III|

* MT-CYB

Complex IV|

* MT-CO1
* MT-CO2
* MT-CO3

ATP synthase|

* MT-ATP6
* MT-ATP8

tRNA|

* MT-TA
* MT-TC
* MT-TD
* MT-TE
* MT-TF
* MT-TG
* MT-TH
* MT-TI
* MT-TK
* MT-TL1
* MT-TL2
* MT-TM
* MT-TN
* MT-TP
* MT-TQ
* MT-TR
* MT-TS1
* MT-TS2
* MT-TT
* MT-TV
* MT-TW
* MT-TY

see also mitochondrial diseases

* v
* t
* e

Enzymes involved in neurotransmission

monoamine|

| histidine → histamine|

| anabolism:|

* Histidine decarboxylase

|

catabolism:|

* Histamine N-methyltransferase
* Diamine oxidase

tyrosine→dopamine→epinephrine|

| anabolism:|

* Tyrosine hydroxylase
* Aromatic L-amino acid decarboxylase
* Dopamine beta-hydroxylase
* Phenylethanolamine N-methyltransferase

|

catabolism:|

* Catechol-O-methyl transferase
* Monoamine oxidase
* A
* B

glutamate→GABA|

| anabolism:|

* Glutamate decarboxylase

|

catabolism:|

* 4-aminobutyrate transaminase

tryptophan→serotonin→melatonin|

* Tryptophan hydroxylase
* Aromatic L-amino acid decarboxylase
* Aralkylamine N-acetyltransferase
* Acetylserotonin O-methyltransferase

arginine→NO|

* Nitric oxide synthase (NOS1, NOS2, NOS3)

choline→Acetylcholine|

| anabolism:|

* Choline acetyltransferase

|

catabolism:|

* Cholinesterase (Acetylcholinesterase, Butyrylcholinesterase)

* v
* t
* e

CH-NH2 oxidoreductases (EC 1.4) - primarily amino acid oxidoreductases

1.4.1: NAD/NADP acceptor|

* Glutamate dehydrogenase
* GLUD1
* GLUD2
* Glutamate synthase (NADPH)

1.4.3: oxygen acceptor|

* D-amino acid oxidase
* Amine oxidase (Copper-containing (Lysyl
* Diamine
* Primary-amine)) (Flavin-containing (Monoamine)))

1.4.4: disulfide acceptor|

* Glycine cleavage system

1.4.99: other acceptors|

* D-amino acid dehydrogenase
* Amine dehydrogenase

* v
* t
* e

Enzymes

Activity|

* Active site
* Binding site
* Catalytic triad
* Oxyanion hole
* Enzyme promiscuity
* Catalytically perfect enzyme
* Coenzyme
* Cofactor
* Enzyme catalysis

Regulation|

* Allosteric regulation
* Cooperativity
* Enzyme inhibitor
* Enzyme activator

Classification|

* EC number
* Enzyme superfamily
* Enzyme family
* List of enzymes

Kinetics|

* Enzyme kinetics
* Eadie–Hofstee diagram
* Hanes–Woolf plot
* Lineweaver–Burk plot
* Michaelis–Menten kinetics

Types|

* EC1 Oxidoreductases (list)
* EC2 Transferases (list)
* EC3 Hydrolases (list)
* EC4 Lyases (list)
* EC5 Isomerases (list)
* EC6 Ligases (list)

* v
* t
* e

Monoamine metabolism modulators

Non-specific|

| AAAD|

* Substrates→Products: L-DOPA (levodopa)→Dopamine
* 5-HTP→Serotonin
* L-Histidine→Histamine
* Phenylalanine→Phenethylamine
* L-Tyrosine→Tyramine
* Tryptophan→Tryptamine

* Inhibitors: Benserazide
* Carbidopa
* DFMD
* Genistein
* Methyldopa

|

MAO|

* Substrates→Products (with ALDH/ALR): Epinephrine (adrenaline)→DHMA
* Metanephrine→MHPG/VMA
* Norepinephrine (noradrenaline)→DHMA
* Normetanephrine→MHPG/VMA
* Dopamine→DOPAC
* 3-Methoxytyramine→HVA
* Serotonin→5-HIAA

* Inhibitors: Non-selective: Benmoxin
* Caroxazone
* Echinopsidine
* Furazolidone
* Guineesine
* Hydralazine
* Indantadol
* Iproclozide
* Iproniazid
* Isocarboxazid
* Isoniazid
* Linezolid
* Mebanazine
* Metfendrazine
* Nialamide
* Octamoxin
* Paraxazone
* Phenelzine
* Pheniprazine
* Phenoxypropazine
* Pivhydrazine
* Procarbazine
* Safrazine
* Tranylcypromine

* Inhibitors: MAO-A-selective: Amiflamine
* Bazinaprine
* Befloxatone
* Brofaromine
* Cimoxatone
* Clorgiline
* CX157 (Tyrima)
* Eprobemide
* Esuprone
* Harmala alkaloids (e.g., harmine, harmaline, harman, norharman, tetrahydroharmine)
* Methylene blue
* Metralindole
* Minaprine
* Moclobemide
* Pirlindole
* Sercloremine
* Tetrindole
* Toloxatone

* Inhibitors: MAO-B selective: Adarigiline
* Almoxatone
* D-Deprenyl
* Ethanol
* Ladostigil
* Lazabemide
* Milacemide
* Mofegiline
* Nicotine
* Pargyline‡
* Rasagiline
* Safinamide
* Selegiline (L-Deprenyl)
* Sembragiline

Phenethylamines
(dopamine, epinephrine,
norepinephrine)|

| PAH|

* Substrates→Products: Phenylalanine→Tyrosine

* Inhibitors: 3,4-Dihydroxystyrene

|

TH|

* Substrates→Products: Tyrosine→L-DOPA (levodopa)

* Inhibitors: 2-Hydroxyestradiol
* 2-Hydroxyestrone
* 3-Iodotyrosine
* Aquayamycin
* Bulbocapnine
* Metirosine
* Oudenone

DBH|

* Substrates→Products: Dopamine→Norepinephrine (Noradrenaline)

* Inhibitors: Bupicomide
* Disulfiram
* Dopastin
* Fusaric acid
* Nepicastat
* Phenopicolinic acid
* Tropolone

PNMT|

* Substrates→Products: Norepinephrine (noradrenaline)→Epinephrine (adrenaline)

* Inhibitors: CGS-19281A
* SKF-64139
* SKF-7698

COMT|

* Substrates→Products: Dopamine→3-Methoxytyramine
* DOPAC→Homovanillic acid
* Norepinephrine→Normetanephrine
* Epinephrine→Metanephrine
* DOPEG→MOPEG
* DOMA→VMA
* 2-Hydroxyestradiol→2-Methoxyestradiol
* 2-Hydroxyestrone→2-Methoxyestrone
* 4-Hydroxyestradiol→4-Methoxyestradiol
* 4-Hydroxyestrone→4-Methoxyestrone

* Inhibitors: 2-Hydroxyestradiol
* 2-Hydroxyestrone
* Entacapone
* Nitecapone
* Opicapone
* Tolcapone

Tryptamines
(serotonin, melatonin)|

| TPH|

* Substrates→Products: Tryptophan→5-HTP

* Inhibitors: AGN-2979
* Fenclonine (PCPA)
* Telotristat ethyl

|

AANAT|

* Substrates→Products: Serotonin→N-Acetylserotonin

ASMT|

* Substrates→Products: N-Acetylserotonin→Melatonin

Histamine|

| HDC|

* Substrates→Products: L-Histidine→Histamine

* Inhibitors: Catechin
* Alpha-Fluoromethylhistidine
* Histidine methyl ester
* Meciadanol
* Naringenin
* Tritoqualine

|

HNMT|

* Substrates→Products: Histamine→N-Methylhistamine

* Inhibitors: Amodiaquine
* Diphenhydramine
* Harmaline
* Metoprine
* Quinacrine
* SKF-91488
* Tacrine

DAO|

* Substrates→Products: Histamine→Imidazole acetic acid

* Inhibitors: Pimagedine (aminoguanidine)

See also: Receptor/signaling modulators • Adrenergics • Dopaminergics • Melatonergics • Serotonergics • Monoamine reuptake inhibitors • Monoamine releasing agents • Monoamine neurotoxins

de:Warrior Gene
*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template
*[AAAD]: Aromatic L-amino acid decarboxylase
*[MAO]: Monoamine oxidase
*[ALDH]: Aldehyde dehydrogenase
*[ALR]: Aldehyde reductase
*[PAH]: Phenylalanine hydroxylase
*[TH]: Tyrosine hydroxylase
*[DBH]: Dopamine beta-monooxygenase
*[PNMT]: Phenylethanolamine N-methyltransferase
*[COMT]: Catechol-O-methyl transferase
*[TPH]: Tryptophan hydroxylase
*[AANAT]: Serotonin N-acetyl transferase
*[ASMT]: Acetylserotonin O-methyltransferase
*[HDC]: Histidine decarboxylase
*[HNMT]: Histamine N-methyltransferase
*[DAO]: Diamine oxidase